Royal Bank of Canada’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-153
| Closed | – | – | 7757 |
|
|
2024
Q1 | $0 | Sell |
153
-147
| -49% | -$111 | ﹤0.01% | 7792 |
|
|
2023
Q4 | $0 | Sell |
300
-362
| -55% | -$264 | ﹤0.01% | 7761 |
|
|
2023
Q3 | $0 | Buy |
662
+379
| +134% | +$466 | ﹤0.01% | 7790 |
|
|
2023
Q2 | $1K | Buy |
+283
| New | +$932 | ﹤0.01% | 7145 |
|
|
2023
Q1 | – | Sell |
-2
| Closed | – | – | 7636 |
|
|
2022
Q4 | $0 | Sell |
2
-27
| -93% | -$139 | ﹤0.01% | 7907 |
|
|
2022
Q3 | $0 | Sell |
29
-2,396
| -99% | -$39.6K | ﹤0.01% | 8028 |
|
|
2022
Q2 | $51K | Sell |
2,425
-3,299
| -58% | -$77.4K | ﹤0.01% | 5711 |
|
|
2022
Q1 | $215K | Buy |
5,724
+2,240
| +64% | +$77.4K | ﹤0.01% | 5020 |
|
|
2021
Q4 | $196K | Buy |
3,484
+1,855
| +114% | +$125K | ﹤0.01% | 5354 |
|
|
2021
Q3 | $117K | Sell |
1,629
-2,669
| -62% | -$204K | ﹤0.01% | 5596 |
|
|
2021
Q2 | $412K | Buy |
4,298
+3,736
| +665% | +$413K | ﹤0.01% | 4453 |
|
|
2021
Q1 | $83K | Buy |
562
+308
| +121% | +$55.8K | ﹤0.01% | 5583 |
|
|
2020
Q4 | $36K | Buy |
254
+164
| +182% | +$26.6K | ﹤0.01% | 5798 |
|
|
2020
Q3 | $14K | Hold |
90
| – | – | ﹤0.01% | 5826 |
|
|
2020
Q2 | $16K | Buy |
+90
| New | +$15.1K | ﹤0.01% | 5677 |
|
|
2019
Q2 | – | Sell |
-1
| Closed | – | – | 7281 |
|
|
2019
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7188 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7224 |
|
|
2018
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 7022 |
|
|
2018
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 6842 |
|
|
2018
Q1 | $0 | Buy |
+1
| New | +$149 | ﹤0.01% | 6909 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6991 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7061 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6834 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6882 |
|
|
2016
Q4 | – | Sell |
-3
| Closed | -$3K | – | 6831 |
|
|
2016
Q3 | $3K | Sell |
3
-45
| -94% | -$48.5K | ﹤0.01% | 6114 |
|
|
2016
Q2 | $52K | Buy |
48
+43
| +860% | +$54K | ﹤0.01% | 5096 |
|
|
2016
Q1 | $6K | Hold |
5
| – | – | ﹤0.01% | 5887 |
|
|
2015
Q4 | $12K | Sell |
5
-8
| -62% | -$12.3K | ﹤0.01% | 5916 |
|
|
2015
Q3 | $14K | Sell |
13
-4
| -24% | -$4.63K | ﹤0.01% | 5731 |
|
|
2015
Q2 | $17K | Hold |
17
| – | – | ﹤0.01% | 5787 |
|
|
2015
Q1 | $17K | Buy |
+17
| New | +$56.1K | ﹤0.01% | 5411 |
|
|
2014
Q3 | – | Sell |
-3
| Closed | -$10K | – | 6168 |
|
|
2014
Q2 | $10K | Buy |
+3
| New | +$11.3K | ﹤0.01% | 5413 |
|
Other funds holding NBSE
Royal Bank of Canada's NBSE Position: Q2 2024 in Review
Royal Bank of Canada sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 153 shares.
Royal Bank of Canada first reported a position in NBSE in Q2 2014 and held it in 28 quarters. The position peaked at $412K in Q2 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.
- Royal Bank of Canada reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 153 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024.
- Royal Bank of Canada first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 28 quarters.
- Royal Bank of Canada's NeuBase Therapeutics, Inc. Common Stock position peaked at $412K in Q2 2021.
- 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.